Want to see PSNL full AI Analyst Report?
PSNL Stock Chart & Stats
$6.73
-$0.70(-11.71%)
At close: 4:00 PM EST
$6.73
-$0.70(-11.71%)
Day’s Range― - ―
52-Week Range$3.84 - $14.83
Previous CloseN/A
Volume738.16K
Average Volume (3M)3.56M
Market Cap
$1.50B
Enterprise Value$831.03M
Total Cash (Recent Filing)$233.22M
Total Debt (Recent Filing)$38.78M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Aug 11, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding104,721,100
10 Day Avg. Volume4,341,035
30 Day Avg. Volume3,561,602
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-8.94
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue12.88
Enterprise Value/Gross Profit93.89
Enterprise Value/Ebitda-9.72
Forecast
1Y Price Target
$11.00Price Target Upside63.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.03
Revenue Forecast (FY)$78.89M
Bulls Say, Bears Say
Bulls Say
Clinical Volume Acceleration And Strong RetentionSustained, rapid clinical test volume growth and physician retention above 98% indicate durable commercial traction and customer stickiness. Higher recurring clinical volumes support predictable revenue scale, data network effects, and the operational leverage needed for long‑term margin improvement as reimbursed tests grow.
Expanding Medicare Reimbursement CoverageBroader payer coverage materially increases addressable market and raises achievable ASPs for NeXT Personal. Durable reimbursement reduces reliance on self‑pay or grant funding, accelerates clinical adoption, and is a structural lever to shift revenue mix toward higher‑margin, repeatable streams if MolDX and payer rollouts continue.
Strong Cash Position And Low LeverageA large cash balance and low debt provide a multi‑quarter runway to invest in MRD commercialization, R&D, and reimbursement efforts without immediate refinancing pressure. This balance sheet flexibility supports strategic patient acquisition and product investment that can establish durable competitive positioning in oncology testing.
Bears Say
Severe Gross Margin CompressionA collapse in gross margin driven by unreimbursed tests and mix shift materially weakens the firm's unit economics. Unless reimbursement and higher‑ASP volumes materialize on schedule, persistently low gross margins will limit the company's ability to fund operations and scale profitably, pressuring long‑term viability.
High And Ongoing Cash BurnSustained negative operating and free cash flow combined with guidance for substantial 2026 cash usage create execution risk. Even with current cash, prolonged burn increases dilution risk or forces cutbacks if reimbursement or commercial conversion lags, constraining long‑term investment in scale and R&D.
Revenue Decline And Customer Concentration RiskA YoY revenue decline and reliance on a few large programs highlight top‑line vulnerability during strategic transition. Intentional migration from legacy revenue to higher‑margin MRD is constructive long term, but until strategic revenue scales, concentration and near‑term revenue volatility threaten sustainable growth and planning.
Personalis News
PSNL FAQ
What was Personalis’s price range in the past 12 months?
Personalis lowest stock price was $3.84 and its highest was $14.83 in the past 12 months.
What is Personalis’s market cap?
Personalis’s market cap is $1.50B.
When is Personalis’s upcoming earnings report date?
Personalis’s upcoming earnings report date is Aug 11, 2026 which is in 34 days.
How were Personalis’s earnings last quarter?
Personalis released its earnings results on May 07, 2026. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.271 by -$0.019.
Is Personalis overvalued?
According to Wall Street analysts Personalis’s price is currently Undervalued.
Does Personalis pay dividends?
Personalis does not currently pay dividends.
What is Personalis’s EPS estimate?
Personalis’s EPS estimate is -0.26.
How many shares outstanding does Personalis have?
Personalis has 104,721,100 shares outstanding.
What happened to Personalis’s price movement after its last earnings report?
Personalis reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.271. Following the earnings report the stock price went down -0.167%.
Which hedge fund is a major shareholder of Personalis?
Currently, no hedge funds are holding shares in PSNL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Personalis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.00 (63.45% Upside)
$11.00 (63.45% Upside)
Hedge Fund Trend
Increased
By 221.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 14.5%
Last 30 Days ▲ 18.0%
Last 30 Days ▲ 18.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
92.48%
12-Months-Change
Fundamentals
Return on Equity
-43.52%
Trailing 12-Months
Asset Growth
19.06%
Trailing 12-Months
Company Description
Personalis
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
PSNL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced strong operational and clinical momentum (rapid test volume growth, compelling real-world and study data, growing MRD pipeline, reimbursement wins and a healthy cash balance) against material near-term financial headwinds (severe gross margin compression, higher operating expenses, widening net loss and elevated cash burn). Management frames the negative margin and revenue mix trends as intentional investments to capture MRD market share and expects margins and ASPs to improve as reimbursed volume scales, but the timing of reimbursement and conversion to higher-margin revenue remains a key risk.View all PSNL earnings summariesPSNL Stock 12 Month Forecast
Average Price Target
$11.00
▲(63.45% Upside)
Technical Analysis
Ownership Overview
13.26% Insiders
11.58% Mutual Funds
50.41% Other Institutional Investors
8.89% Public Companies and
Individual Investors